Our Team

Sergi Sanz is a statistician with over 25 years of experience in biomedical research and nearly 90 scientific publications. He holds a degree in Statistics from the Polytechnic University of Catalonia and a degree in Market Research from the Open University of Catalonia. He also completed a postgraduate program in Advanced Methods of Applied Statistics at UNED and a master’s in Data Management and Knowledge from the Open University of Catalonia.

His career began at the Catalan Institute of Oncology, where he worked in data management and statistical analysis. One of his cancer research projects served as his final degree thesis. He later joined Pedro Alonso's research group at the Hospital Clínic of Barcelona, contributing to its evolution through institutions such as Fundació Clínic, CRESIB, and ISGlobal.

Sergi Sanz coordinates the Biostatistics and Data Management Unit (UBIOES-GD) at ISGlobal, leading institutional data harmonization efforts. He contributes to multicenter projects on tropical diseases like Malaria and Chagas and other infectious diseases.

He is also an associate professor in the Department of Public Health at the Faculty of Medicine of the University of Barcelona and a Biostatistics coordinator for the Master's Degree in Global Health at the same university.

Lines of research

• Data Anonymization
• Data Analyst in Chagas and Malaria diseases
• Data FAIR
• Training in Statistics

Main publications

• Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, Tobias A, Peñafiel J, Ballana E, Pérez CA, Admella P, Riera-Martí N, Laporte P, Mitjà J, Clua M, Bertran L, Sarquella M, Gavilán S, Ara J, Argimon JM, Cuatrecasas G, Cañadas P, Elizalde-Torrent A, Fabregat R, Farré M, Forcada A, Flores-Mateo G, López C, Muntada E, Nadal N, Narejos S, Nieto A, Prat N, Puig J, Quiñones C, Ramírez-Viaplana F, Reyes-Urueña J, Riveira-Muñoz E, Ruiz L, Sanz S, Sentís A, Sierra A, Velasco C, Vivanco-Hidalgo RM, Zamora J, Casabona J, Vall-Mayans M, González-Beiras C, Clotet B. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. N Engl J Med. 2021 Feb 4;384(5):417-427. doi: 10.1056/NEJMoa2021801. Epub 2020 Nov 24. PubMed PMID: 33289973; PubMed Central PMCID: PMC7722693.
• Mitjà O, Houinei W, Moses P, Kapa A, Paru R, Hays R, Lukehart S, Godornes C, Bieb SV, Grice T, Siba P, Mabey D, Sanz S, Alonso PL, Asiedu K, Bassat Q. Mass treatment with single-dose azithromycin for yaws. N Engl J Med. 2015 Feb 19;372(8):703-10. doi: 10.1056/NEJMoa1408586. PubMed PMID: 25693010.
• Mitjà O, Godornes C, Houinei W, Kapa A, Paru R, Abel H, González-Beiras C, Bieb SV, Wangi J, Barry AE, Sanz S, Bassat Q, Lukehart SA. Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study. Lancet. 2018 Apr 21;391(10130):1599-1607. doi: 10.1016/S0140-6736(18)30204-6. Epub 2018 Feb 7. PubMed PMID: 29428183; PubMed Central PMCID: PMC5920722.
• González R, Nhampossa T, Mombo-Ngoma G, Mischlinger J, Esen M, Tchouatieu AM, Mendes A, Figueroa-Romero A, Zoleko-Manego R, Lell B, Lagler H, Stoeger L, Dimessa LB, El Gaaloul M, Sanz S, Méndez S, Piqueras M, Sevene E, Ramharter M, Saúte F, Menendez C. Safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnant women with HIV from Gabon and Mozambique: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2024 May;24(5):476-487. doi: 10.1016/S1473-3099(23)00738-7. Epub 2024 Jan 12. PubMed PMID: 38224706.
• Rojas Panozo L, Rivera Nina S, Wehrendt DP, Casellas A, Pinto L, Mendez S, Kuo CW, Lozano DF, Ortiz L, Pinazo MJ, Picado A, Sanz S, Abril M, Gascon J, Wong S, Schijman AG, Torrico F, Alonso-Padilla J. Evaluation and validation of a PrintrLab-based LAMP assay to identify Trypanosoma cruzi in newborns in Bolivia: a proof-of-concept study. Lancet Microbe. 2024 Sep;5(9):100887. doi: 10.1016/S2666-5247(24)00110-1. Epub 2024 Jul 3. PubMed PMID: 38971173.